The unique properties of T-DXd have broadened its therapeutic efficacy in tumors with lower HER2 expression, classified as HER2-low (IHC 1+ or 2+/ISH-negative) and ultralow (IHC 0 with membrane staining) breast cancer (16, 17). This evidence concerns the gene ERBB2 and breast carcinoma.